A Phase 2 interventional study of RDX5791 in Constipation Predominant Irritable Bowel Syndrome, sponsored by Ardelyx. Completed at 16 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-10-15.
Sponsored by Ardelyx · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing tenapanor in Constipation — 3 open to participants now, 4 under way, 3 of them phase 3. tenapanor · Constipation.
Among the 11 studies testing tenapanor in Constipation, this one is the 6th largest by enrollment, is the only one that started in 2011, is one of 3 in phase 2, and was the 1st registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →3 of the 11 studies testing tenapanor in Constipation are open now, in 1 country. Recruiting first, the newest first:
Ardelyx · Sites in United States
Ages 18–80
Cedar Valley Digestive Health Center · Sites in United States
Ages 50–89
Ardelyx · Sites in United States
Ages 6–18
By country, each count listing its studies:
tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 8
First in 2011; this study’s year is marked. 1 started in 2011.
This study's enrollment of 186 is above the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 186 across the 11 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
Ardelyx is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Ardelyx has 9 studies filed under Constipation — fewer than ten, so there is no comparison to draw.
2 of the studies testing tenapanor in Constipation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07382167Phase 3ArdelyxA 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults | 2027-02-26 |
| NCT06460038Cedar Valley Digestive Health CenterTenapanor in Synucleinopathy-Related Constipation | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing tenapanor in Constipation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, Phase 2, randomized, double-blind, placebo controlled study of RDX5791 in subjects with IBS-C. Patients who are 18 to 75 years old, meeting the definition of IBS-C as defined by the Rome III Criteria for the Diagnosis of IBS will undergo a battery of screening procedures to determine eligibility for the trial.
The study will consist of a 2-week treatment-free screening period, a 4-week blinded treatment period, and a 2-week treatment-free follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Capsule that is identical in size and color to other treatments
Drug: RDX5791
10 mg capsule of tenapanor
Drug: RDX5791
30 mg capsule of tenapanor
Drug: RDX5791
100 mg capsule of tenapanor
Drug: RDX5791
Capsule, QD
Complete Spontaneous Bowel Movement (CSBM) Frequency Change From Baseline
Patients complete a phone diary daily. They are asked "how many bowel movements have you had today?" they are then asked for each spontaneous bowel movement (unaided with laxative use) wether there was its was a complete evacuation. if it was then it is a complete spontaneous bowel movement. All CSBMs are added and adjusted for a mean compete sponteneous bowel movement.
Time frame: Baseline and Week 4
Spontaneous Bowel Movement (SBM) Frequency Change From Baseline
Time frame: baseline and week 4
| Milestone | Placebo | 10mg | 30 mg | 100 mg |
|---|---|---|---|---|
| Started | 47 | 46 | 47 | 46 |
| Completed | 43 | 44 | 43 | 43 |
| Not completed | 4 | 2 | 4 | 3 |
Patients complete a phone diary daily. They are asked "how many bowel movements have you had today?" they are then asked for each spontaneous bowel movement (unaided with laxative use) wether there was its was a complete evacuation. if it was then it is a complete spontaneous bowel movement. All CSBMs are added and adjusted for a mean compete sponteneous bowel movement.
| number of bowel movements/week | Placebo | Low Dose | Mid Dose | High Dose |
|---|---|---|---|---|
| Complete Spontaneous Bowel Movement (CSBM) Frequency Change From Baseline | 1.01 ± 2.03 | 1.50 ± 2.09 | 1.54 ± 2.10 | 1.57 ± 2.50 |
| change in number of bowel movements | Placebo | Low Dose | Mid Dose | High Dose |
|---|---|---|---|---|
| Spontaneous Bowel Movement (SBM) Frequency Change From Baseline | 1.58 ± 2.51 | 2.37 ± 2.27 | 2.97 ± 3.13 | 2.81 ± 3.14 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/47 (0%) | 0/47 (0%) | 0/47 (0%) |
| Low Dose | 0/46 (0%) | 2/46 (4.3%) | 0/46 (0%) |
| Mid Dose | 0/47 (0%) | 0/47 (0%) | 0/47 (0%) |
| High Dose | 0/46 (0%) | 0/46 (0%) | 0/46 (0%) |
| Event | Placebo | Low Dose | Mid Dose | High Dose |
|---|---|---|---|---|
| cholecystitisGastrointestinal disorders | 0/47 | 1/46 | 0/47 | 0/46 |
| appendicitisGastrointestinal disorders | 0/47 | 1/46 | 0/47 | 0/46 |
| Age, Continuous(years) | Placebo | Low Dose | Mid Dose | High Dose | Total |
|---|---|---|---|---|---|
| Mean | 47.9 ± 11.97 | 44.4 ± 14.15 | 46.5 ± 9.49 | 43.5 ± 12.31 | 45.6 ± 12.11 |
| Sex: Female, Male(Participants) | Placebo | Low Dose | Mid Dose | High Dose | Total |
|---|---|---|---|---|---|
| Female | 39 | 42 | 39 | 37 | 157 |
| Male | 8 | 4 | 8 | 9 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Low Dose | Mid Dose | High Dose | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 6 | 5 | 8 | 22 |
| Not Hispanic or Latino | 44 | 40 | 42 | 38 | 164 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | Low Dose | Mid Dose | High Dose | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 0 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 12 | 5 | 9 | 10 | 36 |
| White | 34 | 39 | 38 | 36 | 147 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | Low Dose | Mid Dose | High Dose | Total |
|---|---|---|---|---|---|
| Mean | 28.02 ± 5.56 | 27.40 ± 6.97 | 28.58 ± 6.10 | 28.10 ± 4.14 | 28.03 ± 5.74 |
The record gives a start of May 2011, a primary completion of Dec 2011 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2019, 7 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenapanor